{"id":5223,"date":"2024-10-12T15:13:24","date_gmt":"2024-10-12T07:13:24","guid":{"rendered":"https:\/\/flcube.com\/?p=5223"},"modified":"2024-10-13T17:00:38","modified_gmt":"2024-10-13T09:00:38","slug":"eli-lilly-co-partners-with-insitro-to-leverage-ai-in-metabolic-disease-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=5223","title":{"rendered":"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development"},"content":{"rendered":"\n

Eli Lilly & Co. (NYSE: LLY<\/a>), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated steatotic liver disease.<\/p>\n\n\n\n

The financial details of the agreements were not disclosed, including any upfront payments. However, it has been noted that Lilly is poised to receive milestone payments and royalties across the agreements. What sets these agreements apart from other AI-driven drug development deals is the unique flow of assets. Insitro will have the option to in-license a clinical-stage ternary N-acetylgalactosamine (GalNAc) delivery method from Lilly, as per the first two agreements. This method will be employed to enhance the efficacy of two of Insitro’s investigational siRNA therapies, each targeting a specific liver-related metabolic disease.<\/p>\n\n\n\n

The third contract outlines a collaborative effort between Lilly and Insitro to discover and develop an antibody therapy aimed at a novel target for another metabolic disease. The partnership will persist through the preclinical stage and continue until candidate nomination. Post this phase, Insitro is expected to take the lead on clinical development and commercialization strategies.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked…<\/p>\n","protected":false},"author":1,"featured_media":5224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,199,1135,911],"class_list":["post-5223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-eli-lilly","tag-insitro","tag-nyse-lly"],"yoast_head":"\nEli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated steatotic liver disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=5223\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=5223\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-12T07:13:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T09:00:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/13b7db8692ec671af14d4a20c353ec43.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1896\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development\",\"datePublished\":\"2024-10-12T07:13:24+00:00\",\"dateModified\":\"2024-10-13T09:00:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223\"},\"wordCount\":221,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/13b7db8692ec671af14d4a20c353ec43.jpeg\",\"keywords\":[\"AI\",\"Eli Lilly\",\"Insitro\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5223#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=5223\",\"name\":\"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/13b7db8692ec671af14d4a20c353ec43.jpeg\",\"datePublished\":\"2024-10-12T07:13:24+00:00\",\"dateModified\":\"2024-10-13T09:00:38+00:00\",\"description\":\"Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated steatotic liver disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5223\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/13b7db8692ec671af14d4a20c353ec43.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/13b7db8692ec671af14d4a20c353ec43.jpeg\",\"width\":1896,\"height\":1280,\"caption\":\"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5223#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development - Insight, China's Pharmaceutical Industry","description":"Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated steatotic liver disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=5223","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=5223","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-12T07:13:24+00:00","article_modified_time":"2024-10-13T09:00:38+00:00","og_image":[{"width":1896,"height":1280,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/13b7db8692ec671af14d4a20c353ec43.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=5223#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=5223"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development","datePublished":"2024-10-12T07:13:24+00:00","dateModified":"2024-10-13T09:00:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=5223"},"wordCount":221,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=5223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/13b7db8692ec671af14d4a20c353ec43.jpeg","keywords":["AI","Eli Lilly","Insitro","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=5223#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=5223","url":"https:\/\/flcube.com\/?p=5223","name":"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=5223#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=5223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/13b7db8692ec671af14d4a20c353ec43.jpeg","datePublished":"2024-10-12T07:13:24+00:00","dateModified":"2024-10-13T09:00:38+00:00","description":"Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated steatotic liver disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=5223#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=5223"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=5223#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/13b7db8692ec671af14d4a20c353ec43.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/13b7db8692ec671af14d4a20c353ec43.jpeg","width":1896,"height":1280,"caption":"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=5223#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/13b7db8692ec671af14d4a20c353ec43.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5223"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5223\/revisions"}],"predecessor-version":[{"id":5587,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5223\/revisions\/5587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/5224"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}